Home » Sarepta Partners with Army to Develop COVID-19 Treatment
Sarepta Partners with Army to Develop COVID-19 Treatment
Sarepta Therapeutics is teaming up with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to identify potential COVID-19 treatments.
Under the partnership, Sarepta will provide phosphorodiamidate morpholino oligomers (PMOs) – synthetic compounds that have shown potential as treatments for various diseases, including viral infections.
USAMRIID will evaluate the PMOs for their ability to inhibit infection. If the initial results are promising, the partners will consider joint development of COVID-19 treatments.
Upcoming Events
-
18Jul
-
21Oct